IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2006;47:626-633.)
© 2006 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.05-0754
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guo, L.
Right arrow Articles by Cordeiro, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guo, L.
Right arrow Articles by Cordeiro, M. F.

Assessment of Neuroprotective Effects of Glutamate Modulation on Glaucoma-Related Retinal Ganglion Cell Apoptosis In Vivo

Li Guo,1 Thomas E. Salt,2 Annelie Maass,1 Vy Luong,2 Stephen E. Moss,3 Fred W. Fitzke,2 and M. Francesca Cordeiro1

1From the Glaucoma and Optic Nerve Head Research Group, Department of Pathology, and the 2Departments of Visual Science and 3Cell Biology, University College London Institute of Ophthalmology, London, United Kingdom.

PURPOSE. To assess the neuroprotective effects of different glutamate modulation strategies, with a nonselective (MK801) and a selective (ifenprodil) NMDA receptor antagonist and a metabotropic glutamate receptor agonist (mGluR Group II, LY354740), in glaucoma-related in vivo rat models of retinal ganglion cell (RGC) apoptosis.

METHODS. RGC apoptosis was induced in Dark Agouti (DA) rats by staurosporine (SSP) treatment. Single agents MK801, ifenprodil, or LY354740, or MK801 and LY354740 combined, were administrated intravitreally at different doses. Eyes were imaged in vivo using a recently established technique and the results confirmed histologically. The most effective combined therapy regimen of MK801 and LY354740 was then assessed in a chronic ocular hypertension (OHT) rat model with application at 0, 1, and 2 weeks after OHT surgery and the effects assessed as described before.

RESULTS. All strategies of glutamate modulation reduced SSP-induced-RGC apoptosis compared with the control, in a dose-dependent manner: MK801 (R2 = 0.8863), ifenprodil (R2 = 0.4587), and LY354740 (R2 = 0.9094), with EC50s of 0.074, 0.0138, and 19 nanomoles, respectively. The most effective combination dose of MK801 and LY354740 was 0.06 and 20 nanomoles (P < 0.05), respectively, and the optimal timing of the therapy was 0 weeks after OHT surgery (P < 0.05).

CONCLUSIONS. This novel SSP model was validated as a useful tool for screening neuroprotective strategies in vivo. Group II mGluR modulation may be a useful treatment for RGC death. Combination therapy optimized to limit neurotoxic effects of MK801 may be an effective neuroprotective approach in retinal degenerative disease. Furthermore, treatments that minimize secondary RGC degeneration may be most useful in glaucoma.




This article has been cited by other articles:


Home page
 IOVSHome page
S. Schmitz-Valckenberg, L. Guo, A. Maass, W. Cheung, A. Vugler, S. E. Moss, P. M. G. Munro, F. W. Fitzke, and M. F. Cordeiro
Real-Time In Vivo Imaging of Retinal Cell Apoptosis after Laser Exposure
Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2773 - 2780.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
M F. Cordeiro and L. Erskine
Back to basics ephrins, axonal guidance, neuroprotection and glaucoma
Br. J. Ophthalmol., September 1, 2007; 91(9): 1106 - 1106.
[Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Guo, T. E. Salt, V. Luong, N. Wood, W. Cheung, A. Maass, G. Ferrari, F. Russo-Marie, A. M. Sillito, M. E. Cheetham, et al.
Targeting amyloid-beta in glaucoma treatment
PNAS, August 14, 2007; 104(33): 13444 - 13449.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. Fan, X. Li, and N. G. F. Cooper
CaMKII{alpha}B Mediates a Survival Response in Retinal Ganglion Cells Subjected to a Glutamate Stimulus
Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3854 - 3863.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. Harvey and S. K. Chintala
Inhibition of Plasminogen Activators Attenuates the Death of Differentiated Retinal Ganglion Cells and Stabilizes Their Neurite Network In Vitro
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1884 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. Nakazawa, C. Nakazawa, A. Matsubara, K. Noda, T. Hisatomi, H. She, N. Michaud, A. Hafezi-Moghadam, J. W. Miller, and L. I. Benowitz
Tumor Necrosis Factor-{alpha} Mediates Oligodendrocyte Death and Delayed Retinal Ganglion Cell Loss in a Mouse Model of Glaucoma
J. Neurosci., December 6, 2006; 26(49): 12633 - 12641.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. K. P. Sullivan, E. WoldeMussie, L. Macnab, G. Ruiz, and D. V. Pow
Evoked Expression of the Glutamate Transporter GLT-1c in Retinal Ganglion Cells in Human Glaucoma and in a Rat Model.
Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3853 - 3859.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association for Research in Vision and Ophthalmology